Roche’s CNS Drug Pipeline Matures: More Investment, More Promise
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.